ATOS

Atossa Therapeutics, Inc. · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website atossatherapeutics.com
Employees(FY) 11
ISIN US04962H5063

Performance

-7.1%

1W

+1.95%

1M

+55.45%

3M

+130.92%

6M

+78.41%

YTD

+121.13%

1Y

Profile

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines in the areas of unmet medical need in oncology. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201 for lung injury caused by cancer treatment. In addition, the company develops immunotherapy/chimeric antigen receptor therapy programs. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.

Advanced Technical Analysis

Technical Analysis of ATOS 2024-05-10

Overview:

In analyzing the technical indicators for ATOS over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive assessment of the stock's potential price movement. By examining these key factors, we aim to offer valuable insights and predictions for the next few days.

Trend Anal...

See more ...

Recent News & Updates

2024-05-16 18:15
Wall Street Favorites: 3 Biotech Stocks with Strong Buy Ratings for May 2024(Investorplace)
2024-05-14 20:30
Atossa Therapeutics Announces Last Patient, Last Dose in its Phase 2 Karisma-Endoxifen Clinical Trial(Globenewswire)
2024-05-13 02:52
ATOS Stock Earnings: Atossa Therapeutics Beats EPS for Q1 2024(Investorplace)
2024-05-12 20:50
Atossa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update(Globenewswire)
2024-05-06 20:30
Atossa Therapeutics Announces Support of New Breast Cancer Screening Guidelines(Globenewswire)
2024-04-29 22:30
As Early-Onset Breast Cancer Cases Soar in North America and EU, Biotech Ramps Up Response(Prnewswire)
2024-04-28 21:00
Keynotes, Educational Panels and 96 Companies to Present at the Planet MicroCap Showcase: VEGAS on April 30 - May 2, 2024 at the Paris Hotel & Casino in Las Vegas, NV(Accesswire)
2024-04-28 20:30
Atossa Therapeutics Announces Expanded Research Agreement with Weill Cornell Medicine to Further Evaluate Synergy Between Antibody Drug Conjugates (ADCs) and (Z)-Endoxifen(Globenewswire)
2024-04-14 20:30
Atossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO ) in Women with ER+/HER2- Breast Cancer(Globenewswire)
2024-04-10 22:10
Atossa (ATOS) Reports Positive Results From EVANGELINE Study(Zacks)
2024-04-10 20:30
Atossa to Participate in Noble Capital Markets Emerging Growth Healthcare Conference(Globenewswire)
2024-04-08 23:59
Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen(Globenewswire)
2024-04-01 10:53
ATOS Stock Earnings: Atossa Therapeutics Misses EPS for Q4 2023(Investorplace)
2024-04-01 04:00
Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update(Globenewswire)
2024-03-18 20:30
Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved 'Expanded Access' Program for a U.S. Breast Cancer Patient(Globenewswire)
2024-03-17 20:30
Atossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirements(Globenewswire)
2024-03-11 20:30
Atossa Therapeutics Appoints Breast Cancer Specialist Tessa Cigler, M.D., M.P.H. to its Board of Directors(Globenewswire)
2024-03-05 19:30
Data from Atossa's Phase 2 EVANGELINE Clinical Trial to be Presented at American Association for Cancer Research (AACR) Annual Meeting(Globenewswire)
2024-02-21 19:30
Atossa Therapeutics Announces First Patient Dosing of (Z)-Endoxifen in the Ongoing RECAST DCIS Study(Globenewswire)
2024-02-06 19:30
Atossa Therapeutics Announces Full Enrollment of (Z)-Endoxifen Arm of I-SPY 2 Clinical Trial(Globenewswire)
2024-01-08 19:30
Atossa Therapeutics Issues Letter to Shareholders(Globenewswire)
2023-12-17 20:00
Physician-Scientist Steven Quay Speaks to Victor Davis Hanson about lockdowns, mRNA vaccines, and the origins of the COVID virus(Prnewswire)
2023-12-07 20:40
Is Atossa Genetics (ATOS) Outperforming Other Medical Stocks This Year?(Yahoo Finance)
2023-12-03 19:30
Atossa Therapeutics Announces the Appointment of Arezoo Mirad, M.D., as Senior Medical Director(Globenewswire)
2023-11-19 19:30
Atossa Therapeutics Announces Full Enrollment of Phase 2 Karisma-Endoxifen Clinical Trial(Globenewswire)
2023-11-12 20:00
Atossa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update(Globenewswire)
2023-11-08 20:00
Atossa Therapeutics Appoints Financial Executive Jonathan Finn to its Board of Directors(Globenewswire)
2023-10-30 01:00
Quantum Leap Healthcare Collaborative Initiates Landmark Phase 2 RECAST DCIS Platform Trial to Evaluate Alternative DCIS Treatments with Atossa Therapeutics, Havah Therapeutics, and the Menarini Group(Prnewswire)
2023-10-10 20:30
Fast-food consumption by adolescent girls may sow the seeds of breast cancer decades later(Prnewswire)
2023-09-17 21:25
Approximately 30% Of Newly Diagnosed Cancers In Women Will Be Breast Cancers - Atossa Therapeutics Has A Promising Drug To Help With Prevention And Treatment(Yahoo Finance)

Page 1 of 4

previousnext